Status:
RECRUITING
Minimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast Cancer
Lead Sponsor:
Maastricht University Medical Center
Collaborating Sponsors:
Erasmus Medical Center
The Netherlands Cancer Institute
Conditions:
Breast Cancer
Neoadjuvant Therapy
Eligibility:
FEMALE
18+ years
Brief Summary
Today, the majority of clinically node positive (cN+) breast cancer patients is treated with neoadjuvant systemic therapy (NST). Axillary staging and treatment after NST in cN+ patients are areas of c...
Detailed Description
The MINIMAX is a multicenter registry study that includes node positive breast cancer patients, who are treated with NST (chemotherapy and ± immunotherapy), in order to gain insight in the oncologic s...
Eligibility Criteria
Inclusion
- Female patient with unilateral invasive breast cancer and cN1-3
- Pathologically proven positive axillary lymph node
- Planned to undergo neoadjuvant chemotherapy (± immunotherapy), followed by staging and treatment of the breast and axilla
Exclusion
- Clinically node negative breast cancer before NST
- Bilateral invasive breast cancer
- Neoadjuvant endocrine therapy
- Distant metastases (including oligometastatic disease)
- History of invasive breast cancer
- Other malignancies, except for basal/squamous cell skin cancer, and in situ carcinoma of the cervix or breast
- Axillary surgery or radiotherapy before NST (this includes SLNB prior to NST)
Key Trial Info
Start Date :
July 16 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2027
Estimated Enrollment :
549 Patients enrolled
Trial Details
Trial ID
NCT04486495
Start Date
July 16 2020
End Date
July 1 2027
Last Update
August 24 2022
Active Locations (35)
Enter a location and click search to find clinical trials sorted by distance.
1
Jeroen Bosch Hospital
's-Hertogenbosch, Netherlands
2
Northwest Clinics
Alkmaar, Netherlands
3
The Netherlands Cancer Institute
Amsterdam, Netherlands
4
Gelre Hospital
Apeldoorn, Netherlands